严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发
Development of vaccines for SARS-CoV-2.
作者信息
Ng Wern Hann, Liu Xiang, Mahalingam Suresh
机构信息
Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia.
出版信息
F1000Res. 2020 Aug 17;9. doi: 10.12688/f1000research.25998.1. eCollection 2020.
Abstract
COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
摘要
2019年末出现了新型冠状病毒肺炎（COVID-19），并迅速在全球许多国家传播。直到最近才发现致病的严重急性呼吸综合征冠状病毒2（SARS-CoV-2），人群中几乎没有或完全没有天然免疫力。迫切需要疫苗和药物来对抗这一新的大流行病。在短短几个月内，政府、学术界和工业界投入了巨大努力和资源，竞相研发疫苗。本简要综述总结并讨论了应用于疫苗研发的一系列技术，突出了各种方法的优缺点。
相似文献
1
Development of vaccines for SARS-CoV-2.
F1000Res. 2020 Aug 17;9. doi: 10.12688/f1000research.25998.1. eCollection 2020.
2
SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
3
Status of COVID-19 vaccine development.
Tidsskr Nor Laegeforen. 2020 Sep 9;140(13). doi: 10.4045/tidsskr.20.0676. Print 2020 Sep 29.
4
Vaccine designers take first shots at COVID-19.
Science. 2020 Apr 3;368(6486):14-16. doi: 10.1126/science.368.6486.14.
5
Current development of COVID-19 diagnostics, vaccines and therapeutics.
Microbes Infect. 2020 Jul-Aug;22(6-7):231-235. doi: 10.1016/j.micinf.2020.05.001. Epub 2020 May 6.
6
A vaccine is not too far for COVID-19.
J Infect Dev Ctries. 2020 May 31;14(5):450-453. doi: 10.3855/jidc.12744.
7
mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
Virol Sin. 2020 Jun;35(3):259-262. doi: 10.1007/s12250-020-00243-0. Epub 2020 Jun 10.
8
Melanie Saville: the end-to-end process needed for a SARS-CoV-2 vaccine.
Bull World Health Organ. 2020 Sep 1;98(9):588-589. doi: 10.2471/BLT.20.030920.
9
COVID-19 vaccine development pipeline gears up.
Lancet. 2020 Jun 6;395(10239):1751-1752. doi: 10.1016/S0140-6736(20)31252-6.
10
Intensifying vaccine production.
Bull World Health Organ. 2020 May 1;98(5):302-303. doi: 10.2471/BLT.20.020520.
引用本文的文献
1
The Future of mRNA Vaccines: Potential Beyond COVID-19.
Cureus. 2025 May 21;17(5):e84529. doi: 10.7759/cureus.84529. eCollection 2025 May.
2
Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.
Vaccines (Basel). 2024 Dec 12;12(12):1401. doi: 10.3390/vaccines12121401.
3
How a Novel Approach of Allergy Call Center Improved the Management of the Anti-COVID Vaccination Campaign in Piedmont: Italy.
J Epidemiol Glob Health. 2024 Dec;14(4):1764-1770. doi: 10.1007/s44197-024-00309-2. Epub 2024 Oct 14.
4
Exploring the Relation Between Health Literacy, Infodemic, and Acceptance of COVID-19 Vaccination in Iran: A Cross-Sectional Study.
Health Lit Res Pract. 2024 Oct;8(4):e184-e193. doi: 10.3928/24748307-20240607-01. Epub 2024 Oct 8.
5
A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants.
Nat Commun. 2024 Aug 26;15(1):7225. doi: 10.1038/s41467-024-51535-y.
6
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
7
The Effect of COVID-19 Vaccine on Women's Reproductive Health: A Cross-Sectional Study.
Cureus. 2023 Jun 7;15(6):e40076. doi: 10.7759/cureus.40076. eCollection 2023 Jun.
8
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.
Cell Commun Signal. 2023 May 15;21(1):110. doi: 10.1186/s12964-023-01104-5.
9
The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine.
Int J Mol Sci. 2023 Jan 12;24(2):1536. doi: 10.3390/ijms24021536.
10
Microfluidic Manufacture of Lipid-Based Nanomedicines.
Pharmaceutics. 2022 Sep 14;14(9):1940. doi: 10.3390/pharmaceutics14091940.
本文引用的文献
1
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
2
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.
3
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
4
The race for coronavirus vaccines: a graphical guide.
Nature. 2020 Apr;580(7805):576-577. doi: 10.1038/d41586-020-01221-y.
5
The potential danger of suboptimal antibody responses in COVID-19.
Nat Rev Immunol. 2020 Jun;20(6):339-341. doi: 10.1038/s41577-020-0321-6.
6
The COVID-19 vaccine development landscape.
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
7
A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.
Vaccine. 2020 Mar 23;38(14):2943-2948. doi: 10.1016/j.vaccine.2020.02.056. Epub 2020 Feb 24.
8
The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China.
Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14.
9
First Ebola vaccine approved.
Nat Biotechnol. 2020 Jan;38(1):6. doi: 10.1038/s41587-019-0385-7.
10
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.
J Virol. 2020 Feb 14;94(5). doi: 10.1128/JVI.02015-19.
Zotero 插件